Stemline Therapeutics (STML) Files $50M IPO

April 2, 2012 4:12 PM EDT
Get Alerts STML Hot Sheet
Price: $11.83 --0%

Overall Analyst Rating:
    BUY (= Flat)

Trade Now! 
Join SI Premium – FREE
In a Form S-1 late Monday, Stemline Therapeutics (Nasdaq: STML) registered a $50 million initial public offering. The company plans to list on the NASDAQ under the symbol "STML."

The offering is being made through Oppenheimer and JMP Securities.

Stemline is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities

JMP Securities, S1